Stockholder's Equity - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended		12 Months Ended		12 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Feb. 28, 2014	Dec. 31, 2013 SynthRx [Member]	Apr. 30, 2011 SynthRx [Member]	Jun. 30, 2014 ATM Program [Member]	Jun. 30, 2014 Maximum [Member]	Jun. 30, 2013 Maximum [Member]	Dec. 31, 2013 Second Milestone - FDA Acceptance [Member]
Class of Warrant or Right [Line Items]
Common stock, gross sale					$ 30,000,000			$ 12,500,000
Common stock, issued		119,842,541		102,710,286			3,050,851	16,082,449
Weighted-average sales price		$ 0.78
Net proceeds from financing		12,474,478	28,097,500					11,900,000
Common stock, shares issued	56,195,000
Additional shares of common stock purchased using warrants	28,097,500
Securities offered and sold combination		These securities were offered and sold to the underwriters and the public in units with each unit consisting of one share of common stock and one warrant to purchase up to 0.5 of a share of common stock.
Aggregate number of common stock										0.5
Gross proceeds of financing	28,100,000
Additional proceeds from the exercise of warrants	18,300,000	65
Net proceeds from financing	$ 25,700,000
Exercise price of warrants per share	0.65		0.65
Warrants exercisable									Jun. 19, 2018
Repurchase of common stock						1,454,079
Purchase price per share pursuant to the exercise of a repurchase right under the merger agreement				$ 0.001
Additional Common stock shares issued						12,478,050
Shares issued, fully vested shares				8,638,650							3,839,400
Number of warrants expired or cancelled during the period		135,767